

Original Research Article

Extended Spectrum Beta-Lactamases in Clinical Isolates of *Escherichia coli* and *Klebsiella pneumoniae* from University of Uyo Teaching Hospital, Uyo

ABSTRACT

Aims: This study was aimed at investigating the prevalence of ESBL-producing *Escherichia coli* and *Klebsiella pneumoniae* in clinical samples from University of Uyo Teaching Hospital (UUTH), Uyo-Nigeria, and determine the antibiogram of the isolates.

Study Design: This study involved sample collection and laboratory analysis of samples.

Place and Duration of Study: The study was conducted at the University of Uyo Teaching Hospital, Uyo between January and June 2013.

Methodology: Faecal, wound and urine samples were obtained from 280 in- and out-patients attending UUTH, Uyo. *Escherichia coli* and *Klebsiella* isolates obtained were subjected to routine antimicrobial susceptibility testing and tests for ESBL production using the Double Disk Synergy Test (DDST).

Results: ESBL was detected in 40 (47.1%) of the 85 isolates and *E. coli* was the major ESBL producer, 21 (52.5%) followed by *K. pneumoniae*, 19 (47.5%). The detection rates of ESBL producing organisms was higher in female patients (57.5%) than their male counterparts (42.5%), and infants under 1 year of age were among the age brackets with high prevalence of ESBL producing organisms (20%). The ESBL-producers were most frequently detected in paediatric ward, 11 (27.5%); surgical ward, 10 (25.0%) and GOPD, 7 (17.5%). Majority of the isolates encountered were multidrug resistant strains. Tetracycline and Trimethoprim/Sulfamethoxazole were the least effective antimicrobials to *E. coli* and *K. pneumoniae* with susceptibility rates ranging from 14.6% - 24.3%, while less than 50% were Ciprofloxacin sensitive. Carbapenems were the most effective antimicrobials. All isolates were susceptible to Imipenem, while >90% of the isolates were susceptible to Ertapenem.

Conclusion: This study reveals that there is a high prevalence of ESBL-producing organisms in clinical samples, especially isolates from infants, in UUTH, Uyo with attendant high multi-drug resistance to commonly used antimicrobials. There is need for increased ESBL surveillance as it poses serious threat to successful treatment of infections and exacerbates the problem of antimicrobial resistance especially with commonly used drugs in resource poor settings.

Keywords: ESBL, *E. coli*, *K. pneumoniae*, Antimicrobial resistance

INTRODUCTION

The progressive emergence and rapid dissemination of antimicrobial resistance is one of the biggest challenges facing global public health [1]. The accelerated bacterial resistance to antimicrobials has emerged as perhaps the greatest threat worldwide to the favourable outcome of infections both in the hospital settings and in the community. Beta-lactamase production by several gram negative and gram positive organisms is the most important single mechanism of resistance to **Penicillins, Cephalosporins, Monobactams and Carbapenems** [2], which are the most commonly used antimicrobials in treatment of bacterial infections in hospitals [3]. Extended-Spectrum Beta-lactamases (ESBLs) are a group of diverse, complex and plasmid-mediated rapidly evolving enzymes that pose a major therapeutic challenge in the treatment of patients. The ESBLs are able to hydrolyse a broader spectrum of beta-lactam antibiotics than the simple parent beta-lactamases from which they were derived, hence, the term extended spectrum. They are able to inactivate beta-lactam antibiotics containing an oxyimino-group such as oxyimino-cephalosporins (e.g. Ceftriaxone, Cefotaxime, Ceftazidime), oxyimino-monobactam (e.g. Aztreonam) [4], as well as the Penicillins [5].

ESBLs are most commonly produced by *E. coli* and *Klebsiella* species, with *Klebsiella pneumoniae* seemingly the major ESBL producer [6]. Other members of the Enterobacteriaceae family producing ESBLs include *Salmonella* species, with a growing incidence [7], *Citrobacter freundii*, *Enterobacter aerogenes* and *Proteus mirabilis* [8]. Non-Enterobacteriaceae ESBL producers are relatively rare with *Pseudomonas aeruginosa* being the most important organism [9]. Others reported include *Acinetobacter* species, *Burkholderia cepacia* and *Alcaligenes faecalis* [4].

Organisms producing ESBL have been increasingly detected worldwide with prevalence rates varying from country to country and from institution to institution [6]. A survey carried out from 1997 to 2002 in some countries put the prevalence rate of ESBL producing *Klebsiella* species at 42.7% in

59 Latin America, 21.7% in Europe and 5.8% in North America [7]. The Pan European Antimicrobial
60 Resistance using Local Surveillance (PEARLS) study (2001-2002) showed that Egypt had the highest
61 prevalence of 38.5%; Greece, 27.4%; while the lowest, 2% and 2.6% were reported in Netherlands
62 and Germany respectively [10]. In the USA, the prevalence ESBL producing *Klebsiella* species
63 ranged from 0 – 25% with the national average being around 3% [11]. In Japan, the prevalence of
64 ESBL producing *E. coli* and *Klebsiella pneumoniae* organisms remains low at 0.1% and 0.3%
65 respectively [12]. Some studies have been carried out in Nigeria especially in the South East with
66 reports of ESBL-producing bacteria ranging from as low as 2.5% to as high as 76.9% prevalence
67 [13,14]. Nevertheless, the prevalence of ESBL-producing organisms in many hospitals in Nigeria as
68 well as ESBL types remains unknown [15,16]. Therefore, the objective of this study was to investigate
69 the prevalence of ESBL-producing *Escherichia coli* and *Klebsiella pneumonia* from clinical samples in
70 University of Uyo Teaching Hospital (UUTH), Uyo.

71 MATERIALS AND METHODS

72

73 Study population

74 This study was carried out at the University of Uyo Teaching Hospital (UUTH), being a referral
75 and tertiary health facility located in Uyo, the capital of Akwa Ibom State, Niger Delta region of
76 Nigeria. Patients attending the out-patient clinics and in-patients at UUTH, Uyo were recruited into the
77 study following informed consent. They included patients from Surgical, Paediatric, General
78 Outpatient Department (GOPD), Medical and Antenatal clinic attendees. Others were from Accident
79 and Emergency, Gynaecology, Orthopaedic and Staff clinics of the Hospital. The age group of
80 patients recruited ranged from <1 to 82 yr.. Ethical Approval was sought and obtained from the
81 institutional ethical review board of UUTH, Uyo.

82

83 Sample collection, culture and identification of isolates

84 A total of 280 samples were collected comprising stool, urine and superficial wound swabs.
85 Samples were cultured on Blood and MacConkey agars (Biomark, India) overnight at 37°C.
86 *Escherichia coli* and *Klebsiella pneumoniae* isolates were identified on the basis of conventional
87 microbiological procedures [17].

88

89

Antimicrobial susceptibility testing

Antimicrobial susceptibility assay was performed according to Clinical Laboratory Standards Institute (CLSI) guidelines (20) using the Kirby-Bauer disc diffusion method to evaluate the sensitivity of the test organisms. Antimicrobial agents used include Ciprofloxacin (5µg), Tazobactam-Piperacillin (10/100µg), Cefotaxime (30µg), Gentamicin (10µg), Aztreonam (30µg), Cefpodoxime (10µg), Ceftazidime (30µg), Tetracycline (10µg), Ertapenem (10µg), Imipenem (10µg), and Trimethoprim-Sulfamethoxazole (1.25/23.75µg) (Oxoid, UK). The results were interpreted according to the CLSI guidelines [18]. *Escherichia coli* American Type Culture Collection (ATCC) 25922 reference strain was used as control to test the performance of the method.

Double Disk Synergy Test for ESBL

Isolates with zone diameters suspicious of ESBL production as pre-determined by the susceptibility test results (Cefpodoxime: ≤17mm; Ceftazidime: ≤22mm; Aztreonam: ≤27mm; Cefotaxime: ≤27mm) were subjected to the Double Disk Synergy Test [19] to test for the presence of ESBL producing enzymes.

Briefly, test organisms (suspected of ESBL production) were cultured overnight on nutrient agar, and a suspension prepared to match a 0.5 McFarland turbidity standard was inoculated on the surface of each of the molten Mueller Hinton agar plates using a sterile swab. Amoxicillin (20µg)/Clavulanic acid (10µg) combination disc was placed at the center of each inoculated Mueller–Hinton agar plate. Cefotaxime (30ug), Ceftazidime (30ug), Aztreonam (30µg) and Cefpodoxime (10µg) single discs were then placed 20mm (center to center) from the Amoxycillin/Clavulanic acid disc and incubated at 37°C overnight (18-24hr).

Enhancement of the zones of inhibition of any of the cephalosporin beta-lactam antibiotic discs (i.e. Cefotaxime, Aztreonam, Cefpodoxime or Ceftazidime) towards the Amoxycillin/Clavulanic acid disc caused by the synergy with clavulanate was taken as an evidence of ESBL production. *Escherichia coli* ATCC 25922 (β-lactamase negative), *Klebsiella pneumoniae* ATCC 700603 (ESBL-producer) were used as reference strains for quality control.

RESULTS

The Antimicrobial susceptibility pattern of *E. coli* and *K. pneumoniae* isolates from clinical samples in UUTH, Uyo are shown in table 1. Imipenem was the most effective antimicrobial agent with 100% activity against all the isolates. Ertapenem was sensitive to 93.7% of *E. coli* and 91.9% of *K. pneumoniae* isolates. Tetracycline and Trimethoprim/Sulfamethoxazole were the least effective antimicrobials to *E. coli* with susceptibility rates of 16.7% and 14.6% respectively and 24.3% each for *K. pneumoniae*.

Table 2 shows the prevalence of extended-spectrum Beta-lactamase organisms isolated from clinical samples in UUTH, Uyo. Of the 85 bacterial isolates obtained, 40 were ESBL-producing organisms giving a prevalence rate of 47.1%. Out of a total of 40 ESBL producing organisms, *E. coli* was the major ESBL producer 21 (52.5%) followed by *K. pneumoniae*, 19 (47.5%).

The age and gender distribution of ESBL-producing organisms in UUTH, Uyo are shown in table 3. Generally, infants under 1 year had relatively high prevalence (20%) of ESBL-producing organisms than older children, while females were detected with the highest rate, 23 (57.5%) of ESBL-producing bacteria compared with their male counterparts, 17 (42.5%). The gender difference in the isolation rates was not statistically significant ($P>.05$). Specifically, ESBL-producing *K. pneumoniae* were more frequently isolated in females than in males, so also were ESBL-producing *E. coli* isolates.

The distribution of ESBL producers according to ward/clinic in UUTH, Uyo is shown in table 4. ESBL-producing organisms were most frequently encountered in the Paediatric ward, 11 (27.5%) closely followed by the Surgical ward, 10 (25.0%), then GOPD, 7 (17.5%). No ESBL producer was encountered among isolates from the Orthopaedic and Surgical wards.

DISCUSSION

The prevalence of ESBL-producing organisms has been increasing rapidly worldwide. This situation is alarming because ESBL producers have been reported to exhibit co-resistance to many other classes of antibiotics resulting in limited therapeutic options [5]. In addition, the prevalence of ESBL, type of enzyme, gender and age group of persons affected varies in different geographical areas.

In this study, the overall prevalence of ESBL producing isolates from clinical samples was 47.1%. This is comparable to 39.8% reported in Enugu [13] and 33.6% in Abuja [20]. Higher prevalence rates of 58.6% (Enugu) and 76.9% (Ibadan) have been reported in other Nigerian studies [15,16]. Global reports show that Pakistan [21], Sudan [22] and India [23] recorded 29.45%, 59.6% and 57.5% prevalence respectively. The variation in ESBLs prevalence rates reported between geographical areas, institutions and countries may be attributed to the complex epidemiology of ESBLs, specific type of bacteria involved and methods used for ESBL detection among other factors [6,24].

In this study, *E. coli* was identified as the major ESBL producing microorganism (52.5%) followed by *K. pneumoniae* (47.5%). *E. coli* has recently been reported as the major ESBL producer in similar studies conducted in Enugu [16], Osun [25] and Ogun States [14] as well as in Bangladesh [26] and Pakistan [21]. However, other Nigerian reports, Ogun [27], Benin [28] and Abuja [20] as well as Ghana [29] and Sudan [22] indicated *K. pneumoniae* as the major ESBL producer. Even though both organisms have been identified in various studies within and outside Nigeria as the major ESBL producing microorganisms, there has been no consensus on which has a greater capacity to produce ESBL.

Regarding gender classification, the fact that more ESBL producing organisms were recovered from females than their male counterparts, the difference was however not statistically significant and similar results have been documented elsewhere, Abuja, Nigeria [20] and Pakistan [21]. Children under one year of age were among the age brackets with high prevalence of ESBL producing organisms in this study (20%). Similar high prevalence have been reported elsewhere [14,30]. This observation has serious therapeutic implications that may impact on clinical outcomes in infants. More so, ESBL producing organisms have been associated with increased mortality and morbidity [31].

In this study, it was observed that ESBL producers were most frequently encountered in the Paediatric ward (27.5%) closely followed by surgical wards (25.0%) and General Outpatient Department (GOPD) (17.5%). A study by Alipourfard and Nili [26] reported most of the ESBL-producing isolates (29.6%) were from the medical wards, followed by outpatient's clinic (24.3%).

Majority of the isolates encountered in this study were multidrug resistant strains showing resistance to 4 to 5 antimicrobials or more. The gross misuse or over-use of antimicrobials in the

hospital, non-compliance or adherence of antimicrobial use by patients, could lead to development of multidrug resistant bacteria [2,4]. The existence of ESBL-producers in an individual could lead to increased antibiotic resistance because the plasmid which carries the ESBL enzymes also harbour resistance genes to other classes of antimicrobials [33].

Findings from this study shows that Imipenem is the drug of choice against ESBL-producers followed by Ertapenem as equally reported in other studies [34]. Commonly used antimicrobials in our locality such as Trimethoprim/Sulfamethoxazole, Tetracycline and Ciprofloxacin were among the least effective against the ESBLs as observed in this study. The reason could be attributed to the gross misuse and abuse of these inexpensive antimicrobials which are readily available as over-the-counter (OTC) drugs and can even be purchased without doctor's prescription. Consequently, this poses problems for treatment of infections caused by ESBL producers because these commonly used antimicrobials are usually ruled out in therapeutic options. However, Imipenem and which is the most effective drug against ESBL-producing organism is very expensive and is a broad spectrum antimicrobial. Also, its indiscriminate use could result in the development of Imipenem-resistant strains leaving no therapeutic alternative in the future.

There is an increased need to detect ESBL-producing gram negative bacteria in routine microbiological work. Rapid detection of ESBL is important, not only for treatment guidelines but also to facilitate improved prevention of nosocomial infections [34]. Failure to detect ESBL-mediated resistance has led to therapeutic failure and facilitated the spread of ESBL-producing organism. For cost-effective isolation and effective medical treatments, there is a need to screen patients for ESBL production [35].

CONCLUSIONS

The findings from this study showed that there is a high prevalence of ESBL-producing organisms in clinical samples, especially isolates from infants in University of Uyo Teaching Hospital, Uyo-Nigeria. Majority of the ESBL enzymes producers in this study were *E. coli* strains. Most of the organisms isolated were multidrug resistant strains while the ESBL producers further compounded the problem by exhibiting co-resistance to other classes of antimicrobials including the Fluoroquinolones and Aminoglycosides. However, the Carbapenems remain the most effective therapeutic option for both ESBL and non-ESBL producing organisms, Imipenem being the most effective followed by Ertapenem. There is need for increased surveillance of ESBL producing

organisms as they pose serious threat to successful treatment of infections and exacerbates the problem of antimicrobial resistance in the hospitals, especially in resource poor settings.

REFERENCES

- 1) American Academy of Microbiology. Antibiotic Resistance: An Ecological Perspective of an Old Problem. Washington DC: ASM Press; 2009.
- 2) Chaudhary U, Aggarwal R. Extended Spectrum Beta-lactamases (ESBL) – An Emerging Threat to Clinical Therapeutics. Indian Journal of Medical Microbiology. 2004;22:75-80.
- 3) Kotra LP, Samama J, Mobashery S. Beta-lactamases and Resistance to Beta-lactam Antibiotics. In: Lewis K, Slayters AA, Taber HW, Wax RG, editors. Bacterial Resistance to Antimicrobials. New York: Marcel Decker; 2002.
- 4) Bradford PA. Extended-spectrum Beta-lactamases in the 21st Century: Characterization, Epidemiology, and Detection of this Important Resistance Threat. Clinical Microbiology Reviews. 2001;14:939-51.
- 5) Nathisuwan S, Burgess DS, Lewis II, JS. ESBLs: Epidemiology, Detection and Treatment. Pharmacotherapy. 2001;21:920-28.
- 6) Al-Jasser AM. Review Article: Extended-spectrum Beta-lactamases (ESBLs): A Global Problem. Kuwait Medical Journal. 2006;38:171-85.
- 7) Beindebach DJ, Moet GJ and Jones RN. Occurrence and Antimicrobial Resistance Pattern Comparisons among Blood-Stream Infection Isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagnostic Microbiology and Infectious Diseases. 2004;50:59-69.
- 8) Marchandin H, Carriere C, Sirot D, Jean-Pierre H, Darbas H. TEM-24 Produced by Four Different Species of *Enterobacteriaceae*, Including *Providencia rettgeri*, in a Single Patient. Antimicrobial Agents and Chemotherapy. 1999;43:2069-73.

- 233 9) Nordmann P, Guibert M. Extended Spectrum β -lactamases in *Pseudomonas*
234 *aeruginosa*. Journal of Antimicrobial Chemotherapy. 1998;42:128-31.
- 235 10) Bouchillon SK, Johnson BM, Hoban DJ, Johnson JL, Dowzicky MJ, Wu DH, Visalli
236 MA, Bradford PA. Determining Incidence of Extended Spectrum β -Lactamase
237 Producing Enterobacteriaceae, Vancomycin-resistant *Enterococcus faecium* and
238 Methicillin-resistant *Staphylococcus aureus* in 38 Centres from 17 Countries; The
239 PEARLS Study 2001-2002. International Journal of Antimicrobial Agents. 2004;24:
240 119-124.
- 241 11) Centers for Disease Control (2013). National Nosocomial Infections Surveillance.
242 Available at: <http://www.cdc.gov/ncidod/hip/SURVEILL/NNIS.HTM>. Accessed on
243 15 September, 2013.
- 244 12) Kruokawa H, Shibata N, Shibayama K, Arakawa YA. A Preliminary Survey of
245 Extended-Spectrum β -lactamases (ESBLs) in Clinical Isolates of *Klebsiella*
246 *pneumoniae* and *Escherichia coli* in Japan. Federation of European Microbiological
247 Societies Microbiology Letters. 2000;184:53-56.
- 248 13) Iroha IR, Ezeifeke GO, Amadi ES, Umezurike CR. Occurrence of Extended Spectrum
249 Beta Lactamase Producing Resistant *Escherichia coli* and *Klebsiella pneumoniae* in
250 Clinical Isolates and Associated Risk Factors. Research Journal of Biological
251 Sciences. 2009;4:588-592.
- 252 14) Adeyankinnu FA, Motayo BO, Akinduti A, Akinbo J, Ogiogwa JI, Aboderin BW,
253 Agunlejika RA. A Multicentre Study of Beta-Lactamase Resistant *Escherichia coli*
254 and *Klebsiella pneumoniae* Reveals High Level Chromosome Mediated Extended
255 Spectrum β -Lactamase Resistance in Ogun State, Nigeria. Interdisciplinary
256 Perspectives on Infectious Diseases. 2014;819-96.

- 257 15) Okesola AO, Adeniji TW. Pattern of Extended Spectrum Beta-lactamases Production
258 among Clinical Isolates of *Proteus* Species in Western Nigeria. World Journal of
259 Medical Sciences. 2010;5:94-97.
- 260 16) Iroha IR, Amadi ES, Oji AE, Nwuzo AC, Ejike-Ugwu PC. Detection of Plasmid
261 Borne Extended Spectrum Beta-Lactamase Enzymes from Blood and Urine Isolates of
262 Gram-negative Bacteria from a University Teaching Hospital in Nigeria. Current
263 Research in Bacteriology. 2010;3:77-83.
- 264 17) Cheesbrough M. District Laboratory Practice in Tropical Countries. 2nd ed., London:
265 Cambridge University Press, 2006.
- 266 18) Clinical and Laboratory Standards Institute. *Performance Standards for Antimicrobial*
267 *Susceptibility Testing; Twenty-third Informational Supplement*. CLSI Document
268 M100-S23, Pennsylvania: Clinical and Laboratory Standards Institute, 2013.
- 269 19) Jarlier V, Nicolas M, Fournier G, Philippon A. Extended Spectrum Beta-lactamases
270 Conferring Transferable Resistance to Newer β -lactam Agents in Enterobacteriaceae,
271 Hospital Prevalence and Susceptibility Patterns. Review of Infectious Diseases. 1988;
272 10:867-78.
- 273 20) Akanbi BO, Ojonuba BD, Njoku R. Detection of Extended Spectrum β -Lactamase
274 Producing *Klebsiella pneumoniae* and *Escherichia coli* in Two Hospitals in the
275 Federal Capital Territory, Abuja, Nigeria. Open Journal of Medical Microbiology.
276 2013;3:207-12.
- 277 21) Riaz S, Faisal M, Hasnain S. Prevalence and Comparison of Beta-lactamase
278 Producing *Escherichia coli* and *Klebsiella spp* from Clinical and Environmental
279 Sources in Lahore, Pakistan. African Journal of Microbiology Research. 2012;6:465-
280 470.

- 281 22) Ahmed BO, Omar AO, Asghar AH, Elhassan MM. Increasing Prevalence of ESBL-
282 Producing Enterobacteriaceae in Sudan Community Patients with UTIs. Egyptian
283 Academic Journal of Biological Science. 2013;5:17-24.
- 284 23) Rao SPN, Rama PS, Gurushanthappa V, Manipura R, Srinivasan K. Extended-
285 spectrum Beta-lactamases Producing *Escherichia coli* and *Klebsiella pneumoniae*: A
286 Multi-centric Study across Karnataka. Journal of Laboratory Physicians. 2014;6:7-13.
- 287 24) Kaur K, Chopra S, Sheevani S, Mahajanare G. Modified Double Disc Synergy Test to
288 Detect ESBL Production in Urinary Isolates of *Escherichia coli* and *Klebsiella*
289 *pneumoniae*. Journal of Clinical and Diagnostic Research. 2013;7:229-33.
- 290 25) Ogbolu, DO, Alli OAT, Olanipekun LB, Ojo OI, Makinde OO. Faecal Carriage of
291 Extended-Spectrum Beta-lactamase (ESBL) Producing Commensal *Klebsiella*
292 *pneumoniae* and *Escherichia coli* from Hospital Out-patients in Southern Nigeria.
293 International Journal of Medicine and Medical Sciences. 2013;5:97-105.
- 294 26) Alipourfard I, Nili NY. Antibigram of Extended Spectrum Beta-lactamase (ESBL)
295 producing *Escherichia coli* and *Klebsiella pneumoniae* Isolated from Hospital
296 Samples. Bangladesh Journal of Medical Microbiology. 2010;4:32-36.
- 297 27) Olowe OA, Aboderin BW. Detection of Extended Spectrum β -lactamase-producing
298 Strains of (*E. coli*) and (*Klebsiella spp*) in a Tertiary Health Centre in Ogun State.
299 International Journal of Tropical Medicine. 2010;5:62-64.
- 300 28) Osazuwa I, Osazuwa EO. Detection of Extended Spectrum Beta-lactamase Producing
301 *Klebsiella pneumoniae* and their Susceptibility Rates to Antibiotics in University of
302 Benin Teaching Hospital, Benin City, Nigeria. Research Journal of Pharmaceutical,
303 Biological and Chemical Sciences. 2011;2:603.
- 304 29) Hackman HK, Osei-Adjei G, Ameko E, Kutsanedzie F, Gordon A, Laryea M, Quaye
305 S, Anison L, Brown CA, Twum-Danso K. Phenotypic Determination and

- 306 Antimicrobial Resistance Profile of Extended Spectrum Beta-lactamases in
307 *Escherichia coli* and *Klebsiella pneumoniae* in Accra, Ghana. Journal of Natural
308 Sciences Research. 2013;3:75-81.
- 309 30) Motayo BO, Akinduti PA, Adeyakinu FA. Plasmid Profiles of Carbapenemase
310 Resistant *E. coli* and *K. pneumoniae* and their Resistant Patterns in Abeokuta, Nigeria.
311 African Health Sciences. 2013;3:43-48
- 312 31) Paterson DL, Bonomo RA. Extended Spectrum Beta-Lactamases: A Clinical Update.
313 Clinical Microbiology Reviews. 2005;18:657-86.
- 314 32) Iroha IR, Esimone CO, Neumann S, Marlinghaus L, Korte M, Szabados F, Gatermann
315 S, Kaase M. First Description of *Escherichia coli* Producing CTX-M-15- Extended
316 Spectrum Beta Lactamase (ESBL) in Out-Patients from South Eastern Nigeria.
317 Annals of Clinical Microbiology and Antimicrobials. 2012;11:19.
- 318 33) Ejikeugwu C, Ikegbunam M, Ugwu C, Eze P, Iroha I, Esimone C. Phenotypic
319 Detection of *Klebsiella pneumoniae* Strains - Producing Extended Spectrum β -
320 Lactamase (ESBL) Enzymes. Scholarly Academic Journal of Biosciences. 2013;1:20-
321 23.
- 322 34) Shah AA, Hasan F, Ahmed S, Hameed A. Extended-Spectrum Beta-Lactamases:
323 Characterization, Epidemiology and Detection. Critical Reviews in Microbiology.
324 2004;30:25-32.
- 325 35) Siegel JD, Rhinehart E, Jackson M, Chiarella I. Management of Multidrug Resistant
326 Organisms in Healthcare Settings. American Journal of Infection Control.
327 2007;35:165-93.
- 328
- 329
- 330
- 331

Table 1: Antimicrobial Sensitivity Pattern of *E. coli* and *K. pneumoniae* Isolates from Clinical Samples

Antimicrobial (µg)	<i>E. coli</i> (n=48)			<i>K. pneumoniae</i> n=37)		
	S %	I %	R %	S %	I %	R %
ATM(30)	58.3	0	41.7	32.4	0	25
CTX (30)	58.3	0	41.7	32.4	0	67.6
CPD (10)	58.3	2.1	39.6	45.9	2.7	51.4
CAZ (30)	54.2	4.2	41.7	40.5	2.7	56.8
CIP (5)	45.8	4.2	50.0	48.6	13.6	37.8
ETP(10)	93.7	6.3	0	91.9	0	8.1
CN (10)	66.8	8.3	22.9	51.4	10.8	37.8
IPM(10)	100.0	0	0	100.0	0	0
TZP (10/100)	62.5	29.2	8.3	67.6	21.6	10.8
TE (30)	16.7	0	83.3	24.3	2.7	73.0
SXT (1.25/23.75)	14.6	0	85.4	24.3	0	75.7

Key: S=Susceptible, I=Intermediate, R=Resistant, ATM=Aztreonam, CTX=Cefotaxime, CPD=Cefpodoxime, CAZ=Ceftazidime, CIP=Ciprofloxacin, ETP=Ertapenem, CN=Gentamicin, IPM=Imipenem, TZP=Tazobactam/Piperacillin, TE=Tetracycline, SXT=Sulfamethoxazole/Trimethoprim

Table 2: Distribution of ESBL producing bacteria among clinical samples in UUTH, Uyo

Sample	No. of Isolates (ESBL producers)			
	No. Tested	<i>E. coli</i>	<i>K. pneumoniae</i>	Total
Stool	47	21 (5)	15 (6)	36 (11)
Urine	173	21 (10)	11 (5)	32 (15)
Wounds	60	6 (6)	11 (8)	17 (14)
Total	280	48 (21)	37 (19)	85 (40)
Percentage ESBL producer	-	43.8	52.5	47.1

Table 3: Age and Gender Distribution of ESBL-producing bacteria from clinical samples in UUTH, Uyo

Patient Group	No. Isolates Tested	ESBL- <i>Escherichia coli</i>	ESBL- <i>Klebsiella pneumoniae</i>	Total (%)
Age group(yr)				
<1	23	3	5	8 (20.0)
1-10	15	2	1	3 (7.5)
11-20	2	0	1	1 (2.5)
21-30	5	1	1	2(5.0)
31-40	18	3	5	8 (20.0)
41-50	9	7	4	11 (27.5)
51-60	8	4	1	5 (12.5)
61-70	3	0	0	0
71-80	2	1	1	2 (5.0)
Total	85	21	19	40 (100.0)
Gender				
Male	41	9	8	17 (42.5)
Female	44	12	11	23 (57.5)
Total	85	21	19	40 (100.0)

351 **Table 4: Distribution of ESBL producing Organisms According to Ward/Clinic in**
 352 **UUTH, Uyo**
 353

Location	No. of isolates	No. ESBL organisms		
		<i>E. coli</i>	<i>K. pneumoniae</i>	Total No. (%)
GOPD (General Outpatient Department)	24	5	2	7 (17.5)
Staff Clinic	2	1	0	1 (2.5)
A&E (Accident and Emergency)	6	1	1	2 (5.0)
Medical Wards	7	2	0	2 (5.0)
GYNAE (Gynaecology Ward)	2	0	1	1 (2.5)
ANW (Antenatal Clinic)	4	1	1	2 (5.0)
Paediatric Ward	22	5	6	11 (27.5)
Orthopaedic Ward	12	2	2	4 (10.0)
Surgical Ward	6	4	6	10 (25.0)
Total (%)	85	21	19	40(100.0)

354